HOME >> MEDICINE >> NEWS
Investigational drug may protect cancer and AIDS patients from side effects of pain relief therapy

A drug developed to relieve one of the major side effects of pain therapy for cancer patients may offer an added benefit for AIDS patients, researchers from the University of Chicago and the Children's Hospital of Philadelphia reported Saturday, October 11, at the 2003 Annual Meeting of the American Society of Anesthesiologists in San Francisco.

Methylnaltrexone (MNTX) was invented to reverse the constipation caused by powerful opioid-based pain relievers such as morphine, OxyContin or Percocet taken by patients with cancer or AIDS. Opiates also appear to increase the ability of HIV to infect certain immune system cells.

This laboratory study found that MNTX blocked increases in HIV entry and replication that occur when immune cells are exposed to therapeutic doses of morphine. In this in-vitro study, very small amounts of methylnaltrexone blocked this process.

"If our studies are borne out in future clinical trials, methylnaltrexone may improve the care of patients who take opioids for pain caused by AIDS," said Jonathan Moss, M.D., Ph.D., professor of anesthesia and critical care at the University of Chicago and director of the study.

Many AIDS patients and more than 500,000 patients with advanced cancer depend on drugs like morphine for pain relief. One side effect of these pain relievers is severe constipation, which can be so distressing that many patients discontinue their pain medication.

Methylnaltrexone was invented to solve this problem by the late Leon Goldberg, a University of Chicago pharmacologist. To help a dying friend with morphine-induced constipation, Goldberg took naltrexone, an established drug that blocks the effects of morphine, and altered it slightly so that it could no longer cross the protective barrier that surrounds the brain.

Consequently, it did not interfere with morphine's effect on pain, which is centered in the brain, but it did block morphine's effects on gut motility, which a
'"/>

Contact: John Easton
jeaston@uchospitals.edu
773-702-6241
University of Chicago Medical Center
14-Oct-2003


Page: 1 2

Related medicine news :

1. Investigational transplant drug effectively preserves kidneys while avoiding toxic side effects
2. Investigational drug may provide new option for preventing transplant organ rejection
3. Investigational drug brings new hope to kidney cancer patients
4. Investigational mesh jackets studied as an experimental therapy for heart failure
5. Investigational oral contraceptive reduces premenstrual and menstrual symptoms
6. Investigational drug study may determine if lung cancer is preventable in cigarette smokers
7. New study in Nature demonstrates protection against cell death during heart attack
8. Simple intervention encourages sun protection behaviors
9. Red wine protects the heart
10. Sunflower seed oil can protect low birth weight babies from infection
11. Physical activity linked to protection from Parkinsons disease

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2016)... (PRWEB) , ... June 26, 2016 , ... PawPaws ... a new product that was developed to enhance the health of felines. The formula ... , The two main herbs in the PawPaws Cat Kidney Support Supplement ...
(Date:6/26/2016)... ... June 26, 2016 , ... Many ... been diagnosed with endometriosis. These women need a treatment plan to not only ... approach that can help for preservation of fertility and ultimately achieving a pregnancy. ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... the "Pharmaceutical Excipients Market by Type (Organic Chemical ... Preservative), Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast ... The global pharmaceutical excipients ... 2021 at a CAGR of 6.1% in the forecast ...
(Date:6/23/2016)... 23, 2016 Roche (SIX: RO, ROG; OTCQX: ... its Elecsys BRAHMS PCT (procalcitonin) assay as a dedicated ... shock. With this clearance, Roche is the first IVD ... solution for sepsis risk assessment and management. ... and PCT levels in blood can aid clinicians in ...
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
Breaking Medicine Technology:
Cached News: